Claris Law Legal Blogging Community

Name:

E-mail:

Phone Number:

Zip Code:

Your Question:

Editor: Jamie Sheller
Profession: Trasylol Attorney

Category: Trasylol News

A researcher from San Francisco was working on a study in 2005 that showed that Trasylol increased the risk of kidney failure. Dr. Joseph Mangano performed the study on data from over 5,000 patients. He believes that for every month that the FDA failed to pull Trasylol from the market 1,000 people died after using the drug. Trasylol is used during open heart surgery to reduce bleeding. It took another large study in Canada before the FDA acted though. Following the BART study Trasylol was pulled from the market in November 2007.

Mangano says the FDA should have pulled Trasylol after his study two years before.

"How many patients according to your analysis would have been saved if the drug had been taken off the market after your first study?" Pelley asks.

"Between my study and November 5, when it was taken off the market, there were approximately 431,000 patients who received the drug. As I calculated, 22,000 lives could have been saved. It's about a 1,000 lives saved per month delay in taking that drug off the market," he says.

Bayer feels if the drug is used according the label the benefit outweighs the risk. Further studies are being conducted on the drug to see if it should return to the market.